These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36204504)

  • 1. Medicine quality in high-income countries: The obstacles to comparative prevalence studies.
    Naughton BD; Akgul E
    Med Access Point Care; 2021; 5():23992026211052272. PubMed ID: 36204504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying market risk for substandard and falsified medicines: an analytic framework based on qualitative research in China, Indonesia, Turkey and Romania.
    Pisani E; Nistor AL; Hasnida A; Parmaksiz K; Xu J; Kok MO
    Wellcome Open Res; 2019; 4():70. PubMed ID: 31131333
    [No Abstract]   [Full Text] [Related]  

  • 4. Surveillance for falsified and substandard medicines in Africa and Asia by local organizations using the low-cost GPHF Minilab.
    Petersen A; Held N; Heide L;
    PLoS One; 2017; 12(9):e0184165. PubMed ID: 28877208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substandard and falsified medical product recalls in Zambia from 2018 to 2021 and implications on the quality surveillance systems.
    Chabalenge B; Jere E; Nanyangwe N; Hikaambo C; Mudenda S; Banda M; Kalungia A; Matafwali S
    J Med Access; 2022; 6():27550834221141767. PubMed ID: 36601496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and Estimated Economic Burden of Substandard and Falsified Medicines in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.
    Ozawa S; Evans DR; Bessias S; Haynie DG; Yemeke TT; Laing SK; Herrington JE
    JAMA Netw Open; 2018 Aug; 1(4):e181662. PubMed ID: 30646106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health interventions to protect against falsified medicines: a systematic review of international, national and local policies.
    Hamilton WL; Doyle C; Halliwell-Ewen M; Lambert G
    Health Policy Plan; 2016 Dec; 31(10):1448-1466. PubMed ID: 27311827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance.
    Pisani E; Hasnida A; Rahmi M; Kok MO; Harsono S; Anggriani Y
    JMIR Public Health Surveill; 2021 Aug; 7(8):e29309. PubMed ID: 34181563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients Access to Medicines - A Critical Review of the Healthcare System in Kenya.
    Toroitich AM; Dunford L; Armitage R; Tanna S
    Risk Manag Healthc Policy; 2022; 15():361-374. PubMed ID: 35256867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001-2011).
    Almuzaini T; Sammons H; Choonara I
    BMJ Open; 2013; 3(7):. PubMed ID: 23883882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Point-of-Care Anti-Counterfeit Medicines Technologies: Awareness and Utilization among Medical Practitioners in Eastern Nigeria.
    Iloh GU; Akodu BA; Emeka EA; Obi IV
    West Afr J Med; 2021 Nov; Vol. 38(11):1029-1035. PubMed ID: 34918894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surveillance for substandard and falsified medicines by local faith-based organizations in 13 low- and middle-income countries using the GPHF Minilab.
    Gnegel G; Häfele-Abah C; Neci R; ; Heide L
    Sci Rep; 2022 Jul; 12(1):13095. PubMed ID: 35908047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future Information Technology Tools for Fighting Substandard and Falsified Medicines in Low- and Middle-Income Countries.
    Rasheed H; Höllein L; Holzgrabe U
    Front Pharmacol; 2018; 9():995. PubMed ID: 30233373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing Medicine Quality by Active Pharmaceutical Ingredient Levels: A Systematic Review and Meta-Analysis across Low- and Middle-Income Countries.
    Ozawa S; Chen HH; Lee YA; Higgins CR; Yemeke TT
    Am J Trop Med Hyg; 2022 Jun; 106(6):1778-1790. PubMed ID: 35895431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancing health system strengthening through improving access to medicines: A review of local manufacturing policies in Ghana.
    Peprah Boaitey K; Tuck C
    Med Access Point Care; 2020; 4():2399202620962299. PubMed ID: 36204087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of drug recalls and quality of pharmaceutical products in Nepal.
    Neupane A; Bastakoti M; Tamang S; Giri B
    BMJ Open; 2022 Jul; 12(7):e053479. PubMed ID: 35788073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of Medicines in Portugal: A Retrospective Review of Medicine Recalls (2000-2015).
    Machado Reis AT; Berardo BFR; Loureiro R
    PDA J Pharm Sci Technol; 2018; 72(1):44-49. PubMed ID: 29030530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Substandard, falsified and unregistered medicines in Latin America, 2017-2018.
    Rojas-Cortés R
    Rev Panam Salud Publica; 2020; 44():e125. PubMed ID: 33033498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory framework in Pakistan: situation analysis of medicine quality and future recommendations.
    Rasheed H; Hoellein L; Bukhari KS; Holzgrabe U
    J Pharm Policy Pract; 2019; 12():23. PubMed ID: 31528352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.